Robert Orenstein - Concepedia

Author

Robert Orenstein

Mayo Clinic in Arizona ORCID

Also Known As

Brandon Verdoorn, R Orenstein, R. Orenstein, ROBERT ORENSTEIN, Robert Orenstein

164

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic in Arizona Mayo Clinic in Florida Mayo Clinic WinnMed Mayo Clinic Hospital

About

Robert Orenstein is an author at Mayo Clinic in Arizona specializing in medicine, infection control, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	1.9K
2	Health Sciences	4	4	1.1K
3	Epidemiology	4	4	1.2K
4	Public Health	2	2	1.1K
5	Allergy	1	1	53

Robert Orenstein

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease Murat Törüner, Edward V. Loftus, William S. Harmsen, Gastroenterology Healthcare-associated InfectionGastroenterologyOpportunistic InfectionsInfection ControlPublic Health	2008	1K
The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study Sahil Khanna, Darrell S. Pardi, Scott Aronson, The American Journal of Gastroenterology	2011	609
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent<i>Clostridium difficile</i>Infection: Results of the PUNCH CD Study Robert Orenstein Clinical Infectious Diseases	2015	188
Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility C Seto, Patricio Jeraldo, Robert Orenstein, Microbiome	2014	159
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection Erik R. Dubberke, Christine H. Lee, Robert Orenstein, Clinical Infectious Diseases	2018	133
An outbreak of Mycobacterium chelonae infections in tattoos Lisa A. Drage, Phillip M. Ecker, Robert Orenstein, Journal of the American Academy of Dermatology Medical MicrobiologyMycobacterium Chelonae InfectionsInfection ControlMedicineClinical Microbiology	2009	108
Asymptomatic Clostridium difficile colonization in a tertiary care hospital: Admission prevalence and risk factors Surbhi Leekha, Kimberly Aronhalt, Lynne M. Sloan, American Journal of Infection Control Tertiary Care HospitalAdmission PrevalenceHealthcare-associated InfectionClinical EpidemiologyHospital Epidemiology	2013	91
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia Zelalem Temesgen, Mariam Assi, Fnu Shweta, Mayo Clinic Proceedings Gm-csf NeutralizationImmunologyInfectious Respiratory DiseaseInfection ControlMedicine	2020	86
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial Robert Orenstein, Erik R. Dubberke, Sahil Khanna, BMC Infectious Diseases	2022	79
A Targeted Strategy to Wipe Out <i>Clostridium difficile</i> Robert Orenstein, Kimberly Aronhalt, James E. McManus, Infection Control and Hospital Epidemiology Medical MicrobiologySanitationDecontaminationHealthcare-associated InfectionTargeted Strategy	2011	76

Page 1